HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zalutsky, M. R. Search for Related Content PubMed PubMed Citation Articles by Zalutsky, M. R.

Current Status of Therapy of Solid Tumors: Brain Tumor Therapy

Departments of Radiology and Biomedical Engineering, Duke University Medical Center, Durham, North Carolina

Treatment of malignant brain tumors with conventional approaches is largely unsuccessful because curative doses generally cannot be delivered without excessive toxicity to normal brain. Radioimmunotherapy is emerging as an attractive alternative for glioma therapy because of the potential for more selectively irradiating tumor cells while sparing normal tissues. Several institutions are engaged in phase I and phase II trials investigating the therapeutic potential of monoclonal antibodies (mAbs) labeled with the ß-emitters ¹³¹I and ⁹⁰Y and the -emitter ²¹¹At in patients with recurrent and newly diagnosed brain tumors. The current status of these trials will be discussed with regard to efficacy, toxicity, and future directions.

Key Words: brain tumor • glioma • ²¹¹At • radionuclide therapy • ¹³¹I

This article has been cited by other articles:

				H. Sontheimer An Unexpected Role for Ion Channels in Brain Tumor Metastasis Experimental Biology and Medicine, July 1, 2008; 233(7): 779 - 791. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy J. Clin. Oncol., February 10, 2006; 24(5): 823 - 834. [Abstract] [Full Text] [PDF]

				T. Back, H. Andersson, C. R. Divgi, R. Hultborn, H. Jensen, S. Lindegren, S. Palm, and L. Jacobsson 211At Radioimmunotherapy of Subcutaneous Human Ovarian Cancer Xenografts: Evaluation of Relative Biologic Effectiveness of an {alpha}-Emitter In Vivo J. Nucl. Med., December 1, 2005; 46(12): 2061 - 2067. [Abstract] [Full Text] [PDF]

				Y. Miao, M. Hylarides, D. R. Fisher, T. Shelton, H. Moore, D. W. Wester, A. R. Fritzberg, C. T. Winkelmann, T. Hoffman, and T. P. Quinn Melanoma Therapy via Peptide-Targeted {alpha}-Radiation Clin. Cancer Res., August 1, 2005; 11(15): 5616 - 5621. [Abstract] [Full Text] [PDF]